NCT05018273View on ClinicalTrials.gov

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

October 9, 2024

Study Completion Date

October 9, 2024

Conditions
Solid Tumors, Adult
Interventions
BIOLOGICAL

VB10.NEO

The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.

Trial Locations (12)

10117

Charité-Universitätsmedizin Berlin, Berlin

63110

Washington University, St Louis

77030

MD Andersson, Houston

94143

The Regents of the University of California, San Francisco

06551

Yale Cancer Institute, New Haven

40202-1840

Norton Cancer Institute, Louisville

Unknown

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg

Hospital Universitario Virgen de la Victoria, Campus Universitario De Teatinos s/n, Málaga

Hospital Universitario Vall d'Hebron, Barcelona

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario La Paz, Madrid

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Vaccibody AS

INDUSTRY

lead

Nykode Therapeutics ASA

INDUSTRY